ClinicalTrials.gg
CompletedNCT03050151Updated Aug 1, 2018

Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis

A Phase 1 interventional study of Dupilumab and Auto-injector Device in Atopic Disorders and Eczema, Atopic, sponsored by Regeneron Pharmaceuticals. Completed at 37 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-08-01.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2017, 9 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
176
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.

Enrollment
19th of 50
176 · median 75
Started
2017
with 3 others
Phase 1
4 of 50
none open now
Registered
17th of 50
by date
Lead sponsor
22 of 50
Regeneron Pharmaceuticals

Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 19th largest by enrollment, is one of 4 that started in 2017, is one of 4 in phase 1, and was the 17th registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing dupilumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

To collect data on actual-use to assess technical performance and user injections of dupilumab auto-injection device by patients with atopic dermatitis (AD).

Read the detailed description

Study is conducted in 2 parts: part A and part B.

Part A - Patients with moderate-to-severe AD will be randomized to receive dupilumab (dose 1) by auto-injector (AI) device or prefilled syringe.

Once part A is completely enrolled, part B will randomize patients with moderate-to-severe AD to receive dupilumab (dose 2) by auto-injector (AI) device or prefilled syringe.

03

Conditions studied

  • Atopic Disorders
  • Eczema, Atopic

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Diagnosis of chronic atopic dermatitis for at least 3 years with inadequate response to topical medications within 6 months before screening
  2. Willing and able to comply with all clinic visits and study-related procedures
  3. Provide signed

Key Exclusion Criteria:

  1. Patient \< 30.0 kilograms (Kg) in weight
  2. Patient who has previously participated in a dupilumab clinical study
  3. Patient who has been treated with the following:

    • An drug within 8 weeks or within 5 half-lives (if known),whichever is longer, before the baseline visit
    • / immunomodulating drugs (e.g., systemic , cyclosporine, mycophenolate-mufti, IFN-γ, Janus kinase inhibitors, azathioprine, methotrexate, etc.) or Phototherapy for AD within 4 weeks before the baseline visit
    • An experimental monoclonal antibody within 5 half-lives or within 6◦months prior to visit 1 if the half-life is unknown
    • Biologic agents within 5 half-lives (if known) or 16 weeks prior to baseline visit, whichever is longer
    • Anti-immunoglobulin E therapy (omalizumab) within 130 days prior to visit 1
    • A live (attenuated) vaccine within 4 weeks before the baseline visit
  4. Patient who has initiated treatment with prescription moisturizers or moisturizers containing additives such as ceramide, hyaluronic acid, urea, or filaggrin degradation products during the screening period (patients may continue using stable doses of such moisturizers if initiated before the screening visit)
  5. Patient who has skin comorbidities that may interfere with study assessments
  6. Patient with a planned or anticipated major surgical procedure during the patient's participation in this study
  7. Women of unwilling to use adequate measures during the study
  8. Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
176 participants (actual)

Study arms

  • Experimental
    1 - Dupilumab (Part A)

    Dose (dose 1) as per protocol delivered by auto-injector device

    Drug: Dupilumab · Device: Auto-injector Device

  • Experimental
    2 - Dupilumab (Part A)

    Dose (dose 1) as per protocol delivered by prefilled syringe

    Drug: Dupilumab · Device: Prefilled syringe

  • Experimental
    3 - Dupilumab (Part B)

    Dose (dose 2) as per protocol delivered by auto-injector device

    Drug: Dupilumab · Device: Auto-injector Device

  • Experimental
    4 - Dupilumab (Part B)

    Dose (dose 2) as per protocol delivered by prefilled syringe

    Drug: Dupilumab · Device: Prefilled syringe

Interventions

  • Administration of dose of Dupilumab as per protocol by auto-injector or prefilled syringe

  • DeviceAuto-injector Device

    Delivery of Dupilumab by auto-injector device

  • DevicePrefilled syringe

    Delivery of Dupilumab by prefilled syringe

06

What researchers measure

Primary outcomes

  1. Number of validated AI device-associated product technical failures (PTFs) during the treatment period divided by total number of actual injections

    Time frame: To week 12

  2. Type of validated AI device-associated PTFs during the treatment period divided by total number of actual injections.

    Time frame: To week 12

Secondary outcomes

  1. Number of patients with an AI device-associated PTF

    Time frame: To week 12

  2. Percentage of patients with an AI device-associated PTF

    Time frame: To week 12

  3. Number of AI device-associated product technical complaints (PTCs) divided by total number of actual injections

    Time frame: To week 12

  4. Type of AI device-associated PTCs divided by total number of actual injections

    Time frame: To week 12

  5. Number of patients with an AI device-associated PTC

    Time frame: To week 12

  6. Percentage of patients with an AI device-associated PTC

    Time frame: To week 12

  7. Number of AI device-associated failed drug deliveries (defined as patient failure to administer the full dose at a given attempt, excluding PTF) divided by total number of actual injections

    Time frame: To week 12

  8. Type of AI device-associated failed drug deliveries (defined as patient failure to administer the full dose at a given attempt, excluding PTF) divided by total number of actual injections

    Time frame: To week 12

  9. Number of patients with an AI device-associated failure to deliver dose

    Time frame: To week 12

  10. Percentage of patients with an AI device-associated failure to deliver dose

    Time frame: To week 12

  11. Number of patients with response to patient satisfaction questions with the AI device

    Time frame: To week 12

  12. Percentage of patients with response to patient satisfaction questions with the AI device

    Time frame: To week 12

07

Study locations

37 sites
  • Regeneron Investigational Site
    Birmingham, Alabama 35205, United States
  • Regeneron Investigational Site
    Birmingham, Alabama 35209, United States
  • Regeneron Investigational Site
    Fort Smith, Arkansas 72916, United States
  • Regeneron Investigational Site
    Long Beach, California 90808, United States
  • Regeneron Investigational Site
    Los Angeles, California 90025, United States
  • Regeneron Investigational Site
    Murrieta, California 92562, United States
  • Regeneron Investigational Site
    Oceanside, California 92056, United States
  • Regeneron Investigational Site
    Orange, California 92868, United States
  • Regeneron Investigational Site
    Rolling Hills Estates, California 90274, United States
  • Regeneron Investigational Site
    Santa Monica, California 90404, United States
  • Regeneron Investigational Site
    Denver, Colorado 80220, United States
  • Regeneron Investigational Site
    Coral Gables, Florida 33613, United States
  • Regeneron Investigational Site
    Tampa, Florida 33612, United States
  • Regeneron Investigational Site
    Normal, Illinois 61761, United States
  • Regeneron Investigational Site
    Skokie, Illinois 60077, United States
  • Regeneron Investigational Site
    Indianapolis, Indiana 46256, United States
  • Regeneron Investigational Site
    Rockville, Maryland 20850, United States
  • Regeneron Investigational Site
    Plymouth, Minnesota 55441, United States
  • Regeneron Investigational Site
    Saint Joseph, Missouri 64506, United States
  • Regeneron Investigational Site
    Berlin, New Jersey 08009, United States
  • Regeneron Investigational Site
    Windsor, New Jersey 08520, United States
  • Regeneron Investigational Site
    Corning, New York 14830, United States
  • Regeneron Investigational Site
    Forest Hills, New York 11375, United States
  • Regeneron Investigational Site
    New York, New York 10029, United States
  • Regeneron Investigational Site
    High Point, North Carolina 27262, United States
  • Regeneron Investigational Site
    Raleigh, North Carolina 27612, United States
  • Regeneron Investigational Site
    Tulsa, Oklahoma 74136, United States
  • Regeneron Investigational Site
    Portland, Oregon 97223, United States
  • Regeneron Investigational Site
    Charleston, South Carolina 29420, United States
  • Regeneron Investigational Site
    Greer, South Carolina 29650, United States
  • Regeneron Investigational Site
    Bellaire, Texas 77401, United States
  • Regeneron Investigational Site
    Fort Worth, Texas 76244, United States
  • Regeneron Investigational Site
    San Antonio, Texas 78213, United States
  • Regeneron Investigational Site
    San Antonio, Texas 78218, United States
  • Regeneron Investigational Site
    Webster, Texas 77598, United States
  • Regeneron Investigational Site
    Norfolk, Virginia 23502, United States
  • Regeneron Investigational Site
    Tacoma, Washington 98405, United States
08

References and documents

Publications

  • Blauvelt A, Guttman-Yassky E, Paller AS, Simpson EL, Cork MJ, Weisman J, Browning J, Soong W, Sun X, Chen Z, Kosloski MP, Kamal MA, Delevry D, Chuang CC, O'Malley JT, Bansal A. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE). Am J Clin Dermatol. 2022 May;23(3):365-383. doi: 10.1007/s40257-022-00683-2. Epub 2022 May 14. PubMed 35567671 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Nov 2017, 8 months.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 8 months is below that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2017
First posted
Feb 10, 2017
StartActual
Feb 28, 2017
Primary completionActual
Nov 14, 2017
CompletionActual
Feb 12, 2018
Last update
Aug 1, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03050151
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Feb 10, 2017
Start date
Feb 28, 2017
Primary completion
Nov 14, 2017
Completion
Feb 12, 2018
Last update
Aug 1, 2018

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion